Evidence map›Paper›PMID 32106499›Full record

ReviewToxins2020

Should We Consider the Cardiovascular System While Evaluating CKD-MBD?

Merita Rroji, Andreja Figurek, Goce Spasovski

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Merita RrojiUniversity Department of Nephrology, Faculty of Medicine, University of Medicine Tirana, Tirana 1001, Albania.
Andreja FigurekInstitute of Anatomy, University of Zurich, 8057 Zurich, Switzerland.ORCID 0000-0003-3766-0312
Goce SpasovskiUniversity Department of Nephrology, Medical Faculty, University of Skopje, Skopje 1000, North Macedonia.
University of Medicine Tirana · ALUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis. The presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) has shown a strong correlation with CV events and mortality. As a non-atheromatous process, it could be partially explained why standard CV disease-modifying drugs do not provide such an impact on CV mortality in CKD as observed in the general population. We summarize the potential association of CV comorbidities with the older (parathyroid hormone, phosphate) and newer (FGF23, Klotho, sclerostin) CKD-MBD biomarkers.

Indexed as

AnimalsAvitaminosisBiomarkersCardiovascular DiseasesCardiovascular SystemChronic Kidney Disease-Mineral and Bone DisorderComorbidityFibroblast Growth Factor-23HumansParathyroid HormonePhosphatesRisk FactorsBiomarkersFGF23 protein, humanFibroblast Growth Factor-23Parathyroid HormonePhosphateschronic kidney diseaseFGF23klotholeft ventricular hypertrophyphosphatePTHsclerostin.uremic cardiopathy

Identifiers

PMID32106499
PMCPMC7150959
OpenAlexW3010629266

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.